News

Beactica signs three-year extension agreement with Sanofi

Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced that it has signed a three-year extension of its master services agreement with Sanofi. The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions... [...]

Beactica signs five-year framework agreement with global pharmaceutical company

Beactica, the Swedish company with unique capabilities to evaluate the interactions of molecules, today announced that it has signed a five-year research services agreement with an undisclosed top-five-ranked global pharmaceutical company. The framework agreement outlines the legal terms under which Beactica will provide... [...]

Beactica awarded funding to develop new therapeutics against aggressive brain tumours

Beactica, the Swedish drug discovery company, today announced that it has been awarded 2 MSEK (~$240 000) by the Swedish Governmental Agency for Innovation Systems (Vinnova) to advance its LSD1 programme. This programme aims to develop a novel class of compounds with the potential to radically improve the current treatment... [...]

Beactica to present at the 15th Annual Discovery On Target Conference in Boston, MA

Beactica AB, the Swedish drug discovery company, today announced that its LSD1 programme has been selected for both an oral and a poster presentation at the 15th Annual Discovery on Target Conference (www.discoveryontarget.com). The conference will take place on September 25–29, 2017 at The Westin Copley Place in Boston,... [...]

Beactica participates in EU training network on fragment-based drug discovery

Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a Marie Curie Initial Training Network (ITN). The ITN, called FRAGNET, is funded with 3.9 MEUR by the EU and aims to deliver 15 skilled early-stage researchers in the field of fragment-based drug discovery (FBDD).“Training... [...]

Beactica announces appointment of Scientific Advisors

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Professor Jan Kihlberg and Dr Vendela Parrow as Scientific Advisors. They will, together with company co-founder Professor Helena Danielson, assist the progression of Beactica’s internal drug discovery programs within oncology... [...]